• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Swedish Orphan Biovitrum

430.40 SEK

-1.06 %

Less than 1K followers

SOBI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.06 %
-2.40 %
+15.45 %
+29.33 %
+32.84 %
+51.02 %
+105.00 %
+191.93 %
+801.95 %

Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.

Read more
Market cap
153.83B SEK
Turnover
107.26M SEK
Revenue
28.24B
EBIT %
3.07 %
P/E
309.64
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
16/7
2026

Interim report Q2'26

27/10
2026

Interim report Q3'26

4/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/11/2026, 6:00 AM

Swedish Orphan Biovitrum AB: Sobi presenterar nya kliniska data och data från klinisk praxis på EHA 2026 i Stockholm

Swedish Orphan Biovitrum
Regulatory press release6/1/2026, 11:44 AM

Finansinspektionen: Flaggningsmeddelande i Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum
Press release6/1/2026, 8:00 AM

Swedish Orphan Biovitrum AB: Sobi presenterar nya data om pegcetacoplan på ERA 2026

Swedish Orphan Biovitrum

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/26/2026, 2:15 PM

Swedish Orphan Biovitrum AB: Ny analys visar att Tryngolza® (olezarsen) vid svår hypertriglyceridemi minskade risken för akut pankreatit med 85 % och sänkte triglyceridnivåerna med 66 %

Swedish Orphan Biovitrum
Press release5/26/2026, 2:15 PM

Swedish Orphan Biovitrum AB: New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

Swedish Orphan Biovitrum
Regulatory press release5/21/2026, 8:30 PM

Swedish Orphan Biovitrum AB: Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Swedish Orphan Biovitrum
Regulatory press release5/21/2026, 8:30 PM

Swedish Orphan Biovitrum AB: Positiva topline-resultat från den pivotala fas 3-studien REDUCE 2 med pozdeutinurad vid gikt

Swedish Orphan Biovitrum
Regulatory press release5/6/2026, 9:45 AM

Swedish Orphan Biovitrum AB: Bulletin from Sobi's Annual General Meeting (AGM)

Swedish Orphan Biovitrum
Regulatory press release5/6/2026, 9:45 AM

Swedish Orphan Biovitrum AB: Kommuniké från Sobis årsstämma

Swedish Orphan Biovitrum
Regulatory press release4/28/2026, 6:00 AM

Swedish Orphan Biovitrum AB: Delårsrapport för första kvartalet 2026: Stark leverans och viktiga framsteg i pipeline

Swedish Orphan Biovitrum
Regulatory press release4/28/2026, 6:00 AM

Swedish Orphan Biovitrum AB: Sobi Q1 2026 report: Strong execution and pipeline momentum

Swedish Orphan Biovitrum
Regulatory press release3/31/2026, 9:00 AM

Swedish Orphan Biovitrum AB: Sobi publishes Annual and Sustainability Report for 2025

Swedish Orphan Biovitrum
Regulatory press release3/31/2026, 9:00 AM

Swedish Orphan Biovitrum AB: Sobi publicerar sin års- och hållbarhetsredovisning för 2025

Swedish Orphan Biovitrum
Regulatory press release3/27/2026, 7:00 AM

Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum
Regulatory press release3/27/2026, 7:00 AM

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum
Press release3/18/2026, 10:05 AM

Swedish Orphan Biovitrum AB: Resultat från fas 2a-studien EMBRACE av emapalumab vid gammainterferondriven sepsis presenterade vid ISICEM

Swedish Orphan Biovitrum
Regulatory press release2/18/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

Swedish Orphan Biovitrum
Regulatory press release2/18/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobis kapitalmarknadsdag 2026: Bringing brillant ideas to life - med ambitionen att nå 55 miljarder kronor till 2030 inleder vi nästa kapitel

Swedish Orphan Biovitrum
Regulatory press release2/5/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi publicerar delårsrapport för fjärde kvartalet och bokslutskommuniké för 2025: Året avslutas med betydande tillväxt och strategiska framsteg

Swedish Orphan Biovitrum
Regulatory press release2/5/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

Swedish Orphan Biovitrum